May 14, 2026 - 18:31

dLocal has reported its financial results for the first quarter of 2026, marking several new milestones for the cross-border payments company. Total Payment Volume surpassed US$14 billion for the first time, representing a 73% increase compared to the same period last year. This marks the sixth consecutive quarter where the company has achieved year-over-year growth of 50% or more.
The company posted a record gross profit of US$119 million, up 40% year-over-year. Operating profit reached US$57 million when excluding prior years tax adjustments, a 25% increase from the prior year. Net income stood at US$52 million excluding those same adjustments, rising 11% year-over-year.
Looking ahead, dLocal expects higher operating expenses stemming from carry-over costs from 2025. However, the company anticipates that operating leverage will improve in the second half of 2026. Adjusted Free Cash Flow came in at US$15 million, driven by temporary factors. The results underscore dLocal's continued expansion in emerging markets and its ability to process growing transaction volumes across its payment platform.
May 14, 2026 - 12:10
ASX Penny Stocks To Watch: Bell Financial Group And Two OthersThe Australian share market has been under pressure lately, weighed down by the latest federal budget and ongoing global economic headwinds. Yet even in a down market, some investors are looking...
May 13, 2026 - 20:03
Should you buy Series I bonds as inflation heats up again?Series I bonds are once again drawing interest from savers looking for a secure way to protect their cash from rising prices. With inflation showing signs of heating up, these government-backed...
May 13, 2026 - 03:39
Nyxoah Reports First Quarter 2026 Financial and Operating ResultsNyxoah SA, a medical technology company developing treatments for Obstructive Sleep Apnea, reported its financial and operating results for the first quarter of 2026 on May 12. The company pointed...
May 12, 2026 - 00:33
Gilead Sciences, Inc. (GILD) Outlook Cut Sharply on $11.5B IPR&D and Financing CostsGilead Sciences, Inc. (GILD) recently saw its fiscal 2026 outlook take a significant hit, with analysts pointing to a massive $11.5 billion charge tied to in-process research and development (IPR&D...